Sign In
Buy NVAX
$10.20
-0.0100 (-0.0979%)
At Close: Jun 03, 2026
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
10:05am, Wednesday, 14'th Aug 2024
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novavax: Staying Long Despite Coming Up Short In Q2
08:27am, Tuesday, 13'th Aug 2024
Novavax reported Q2 earnings with a miss on EPS and revenue, causing a drop in share price, but recovered after the earnings call. Novavax is making progress with internal vaccine candidates, Sanofi p
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
08:56am, Monday, 12'th Aug 2024
Novavax Inc. NASDAQ: NVAX is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases. Its most significant vaccine, Nuvaxovid, is for COVID-19.
Novavax (NVAX) Lags on Q2 Earnings & Sales, Cuts '24 Outlook
12:10pm, Friday, 09'th Aug 2024
Novavax (NVAX) posts dismal second-quarter results. It also slashes its total revenue guidance, citing lower COVID-19 vaccine uptake.
Novavax is a 'super volatile stock,' strategist explains
06:20pm, Thursday, 08'th Aug 2024
Novavax (NVAX) recently reported its second quarter results, missing estimates on revenue and adjusted earnings while slashing its full-year outlook for revenue. Despite this, Novavax's stock edges hi
Novavax, Inc. (NVAX) Q2 2024 Earnings Call Transcript
12:33pm, Thursday, 08'th Aug 2024
Novavax, Inc. (NASDAQ:NVAX ) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Erika Schultz - Senior Director of Investor Relations John Jacobs - President and Chief Exec
COVID-19 Vaccine Maker Novavax Trims Annual Outlook As Q2 Sales Take A Hit
12:32pm, Thursday, 08'th Aug 2024
On Thursday, Novavax Inc NVAX reported second-quarter 2024 sales of $415 million, compared to $424 million a year, missing the consensus of $458.6 million.
Novavax (NVAX) Misses Q2 Earnings and Revenue Estimates
10:15am, Thursday, 08'th Aug 2024
Novavax (NVAX) came out with quarterly earnings of $0.99 per share, missing the Zacks Consensus Estimate of $1.82 per share. This compares to earnings of $0.58 per share a year ago.
Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights
08:02am, Thursday, 08'th Aug 2024
Achieved total revenue of $415 million in the second quarter of 2024 and ended the period with $1.1 billion in Cash Filed with the U.S. FDA and EMA for authorization of updated 2024-2025 formula COVI
Novavax quarterly revenue misses estimate on weak COVID vaccine sales
07:47am, Thursday, 08'th Aug 2024
Novavax reported second-quarter revenue that was below analysts' estimates on Thursday due to lower-than-expected sales of its COVID-19 vaccine.
Novavax (NVAX) Stock Before Q2 Earnings: To Buy or Not to Buy?
11:21am, Monday, 05'th Aug 2024
On Novavax's (NVAX) second-quarter earnings call, investors will likely focus on the company's pipeline updates and collaboration revenue numbers from its recently entered deal with Sanofi.
Where Will Novavax Be in 5 Years?
05:29am, Saturday, 03'rd Aug 2024
Novavax's business has improved over the past 18 months. The company has several important catalysts and potential growth drivers.
Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Note
06:47pm, Thursday, 01'st Aug 2024
The latest trading day saw Novavax (NVAX) settling at $12.57, representing a -1.87% change from its previous close.
Novavax to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Operational Highlights on August 8, 2024
09:25am, Thursday, 01'st Aug 2024
GAITHERSBURG, Md. , Aug. 1, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its secon
JPMorgan Just Cut Its Price Target on These 3 Stocks: July 31, 2024
11:52am, Wednesday, 31'st Jul 2024
Analysts typically issue price ratings in response to a company's earnings reports. So, what's significant about stocks with lowered price targets?
